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Brain metastases (BM) are an ominous com-
plication of cancer that occurs in up to 30% of 
patients with systemic malignancies [1, 2]. Lately 
a raise in the incidence of BM has been appreci-
ated, this might be due to increased awareness by 
oncologists, further imaging surveillance and fit-
ter treatments that boost overall survival [2, 3]. 
Among all types of tumors, the ones that most 
frequently develop BM are lung cancer (LC) and 
breast cancer (BC) [4]. 
Although the location of BM vary in every pa-
tient, they can be broadly sub-divided as either su-
pratentorial (above the tentorium cerebelli — in-
volving the cerebrum) or infratentorial (between 
tentorium cerebelli and foramen magnum — in-
volving the cerebellum and brainstem), consistently, 
the supratentorial compartment displays the major-
ity of the lesions [5]. On the other hand, it has been 
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background: Brain metastases (BM) occur in almost one third of patients with systemic malignancies. Only a small number of 
studies focus on infratentorial location and whole brain radiotherapy (WBrT) as the main non-surgical management. The aim 
of the study was to compare the prognosis of patients treated with WBrT among patients with supra- or infratentorial lesions.
Materials and methods: at a single center, 263 patients with either breast (Bc) or lung (Lc) cancer, that had developed BM 
and received treatment with WBrT, were analyzed during an 8-year period.
results: a total of 152 patients with Bc and 111 with Lc were analyzed, median age at the time of BM was 50.7 years, systemic 
activity other than BM was detected in 91%. Newly diagnosed BM were supratentorial in 40%, infratentorial in 10% and 51% 
in both locations. Median overall survival was 13 months (95% cI: 11.1–14.8 months), without significant difference between 
supra- or infratentorial location. WBrT alone was administered in 79% of patients, whereas WBrT with chemtoreapy was 
provided for 21%.
conclusion: In patients with BM from Lc or Bc that were not candidates for surgical resection, palliative WBrT appears to be 
equally effective in those with supra- or infratentorial locations.
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proposed that patients with metastases located in 
the infratentorial compartment have worse outcome 
owing to the fragile structures that are contained in 
this region and the cumbersome properties of this 
location, such as the osseous boundaries (the clivus 
anteriorly, the temporal bones anterolaterally and 
the occipital bone posteriorly-inferiorly) that be-
have like a protective sanctuary preventing patients 
that develop BM in this location from receiving ap-
propriate doses of radiation. Besides, fragile struc-
tures, such as the brainstem and the cranial nerves, 
futher complicate radiation to this region [5, 6].
Whole brain radiation therapy (WBRT) has 
been a cornerstone tool for the management of 
BM; although it has been associated with adverse 
effects, the effectiveness of this therapy has been 
validated by multiple clinical trials, and when used 
in the proper setting, the benefits outweigh the 
potential unwanted effects [7, 8]. In the palliative 
care context, this therapy is primarily offered to 
patients with BM that are not suitable for surgical 
resection [3]. 
Concomitant treatment of solid tumors with 
WBRT along with systemic therapy has been stud-
ied elsewhere [8, 9]; albeit, to our current knowl-
edge, there is no convincing evidence that simulta-
neous treatment with systemic therapy and WBRT 
significantly improves outcomes. Furthermore, 
modern literature concentrates on surgical and ste-
reotactic radiosurgery approaches [6], whereas only 
a small number of studies focus on infratentorial 
location and WBRT as the main nonsurgical man-
agement [5].
The aim of the present study was to determine if 
the effectiveness of WBRT for palliating infratento-
rial metastases was non-inferior to the effectiveness 
of WBRT for supratentorial metastases, in patients 
with BC and LC.
Materials and methods
This study was designed as a retrospective, sin-
gle center study. All definitions and criteria were 
specified before data collection. Inclusion criteria 
for patients were: 1. ≥ 18 years of age; 2. patholo-
gy-confirmed diagnosis of primary LC or BC; 3. 
new diagnosis of BM between June 1, 2010 and 
June 30, 2018; 4. Patients must have received WBRT 
with conventional megavoltage external beam ra-
diotherapy, administered with a linear accelerator 
(energy 6MV) or with a cobalt bomb (1.25 MV); 
5. T1-contrast MRI obtained prior to WBRT must 
be available; 6. Patients must have attended a neu-
ro-oncology (NeOn) consultation. Exclusion crite-
ria were: 1. incomplete medical record; 2. diagnosis 
of neoplastic meningitis; 3. previous treatment for 
BM; 4. an alternate neurological diagnosis.
Collected characteristics that were obtained from 
medical charts were: age, sex, date of primary can-
cer diagnosis, date of first BM diagnosis, date of last 
follow-up or death, presence of systemic metastasis 
(considered as any metastasis other than a BM), 
total number of BM, localization (supratentorial, 
infratentorial — which included the cerebellum 
and brainstem regions — and side), modality of 
treatment — either WBRT or WBRT with chemo-
therapy (temozolamide) — and score on the Kar-
nofsky Performace Status scale (KPS) at the time of 
BM diagnosis.
statistical analysis
Analyses comparing BC to LC were performed 
using the χ2 test, T-test, or log-rank test accord-
ing to the analyzed variable. Survival comparisons 
were performed by using Kaplan-Meier curves, and 
comparisons among groups were evaluated with 
a Log-Rank test; a predetermined p value < 0.05 
was set to be statistically significant. All statistical 
analyses were performed using IBM SPSS Statistics, 
version 25 (IBM Corp. Armonk, N.Y., USA).
results
A total of 296 patients were sent to the NeOn 
unit for assessment. 33 patients were excluded, 16 
because they had been treated by surgical resec-
tion and 17 because they had received stereotactic 
radiosurgery treatment; accordingly, only 263 pa-
tients were considered for the final analysis. Female 
sex predominated with 221 (84%) patients; at the 
time the analysis was performed 21 (8%) patients 
were still alive. The primary tumor was BC in 152 
(58%) patients and LC in 111 patients (42%); the 
most frequent histological types were HER2+ and 
non-small cell (NSCLC), respectively. Median time 
from the diagnosis of primary tumor to diagnosis 
of BM was 13 months (Range 0–354 months), most 
patients had systemic metastases other than BM 
(91%), other general characteristics of the popula-
tion are described in Table 1. 
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Subgroup analysis and survival outcomes for 
the type of cancer, number of BM, side, presence 
of systemic metastasis, KPS, and time of BM de-
velopment from primary tumor diagnosis accord-
ing to supratentorial, infratentorial, or both are 
available at Table 2. There were no statistically 
significant differences in median overall survival 
(OS) after diagnosis of BM among subgroups. OS 
was 13 months (95% CI: 11–14 months) for all 
patients; 14 months for those with BM exclusively 
at the supratentorial compartment; 14 months for 
those with exclusively infratentorial BM; and 13 
months for patients with supra- and infratentorial 
BM (Fig. 1). Supplementary Table 1 compares OS 
among BC subtypes.
WBRT alone was administered in a total of 208 
patients (79%), among this group, OS after BM di-
agnosis was of 12 months (95% CI: 10–13 months); 
12 months for patients with either supratentorial or 
supra- and infratentorial BM; and only 8 months 
(95% CI: 2.5–13.5 months) for patients with exclu-
sively infratentorial BM. 
Meanwhile, 55 patients (20.9%) received WBRT 
followed by chemotherapy, in this group, median 
OS after BM diagnosis was 24 months (95% CI: 
18–29 months); 26 months for patients with either 
supratentorial-only or infratentorial-only BM; and 
20 months for patients with BM in both compart-
ments. These results can be found in Table 3. 
The most common radiation regimen admin-
istered was a total of 30 Gy distributed in 10 frac-
tions, additional information regarding radiothera-
py treatment is available in Supplementary Table 2. 
Discussion
In our sample of 263 patients, OS was not signifi-
cantly different between patients with infratentorial 
BM and patients with supratentorial BM. Further-
more, we did not identify significant differences 
in OS according to affected side, number of BM, 
presence of other systemic metastases, KPS, or time 
elapsed before development of BM.
With improved radiation techniques, stereo-
tactic radiosurgery is becoming a frequent treat-
ment modality for BM [9, 10]. However, as our 
results suggest, OS in patients with infratentorial 
BM is similar, even in those treated previously with 
SRS or surgery [7], suggesting that WBRT could 
be considered a palliative treatment modality for 
these patients. Previous reports have considered 
radiobiological models providing non-uniform ir-
radiation as a treatment modality in these patients 
[11, 12]. However, our study provides information 
suggesting these approaches might not be needed 
when a homogeneous dose is planned an adminis-
tered as WBRT. 
It is important to consider that concomitant 
and subsequent systemic therapies that are not in-
cluded in this analysis represent a major bias and 
might be a significant confounding variable for 
overall survival. As well, the retrospective design of 
table 1. General characteristics for patients with breast or lung cancer who developed brain metastases
Primary cancer
Breast 
(n = 152) (%)
Lung  
(n = 111) (%)
Total 
(n = 263) (%)
p-value
sex
Female 152 (100) 69 (62) 221 (84)
*< 0.0001
Male - 42 (38) 42 (16)
systemic metastases 144 (95) 95 (86) 239 (91) *< 0.01
contralateral lung 68 (45) 21 (19) 89 (34) *< 0.0001
Liver metastases 52 (34) 25 (23) 77 (29) *0.027
Bone metastases 88 (58) 69 (62) 157 (60) *0.28
Median age at cancer diagnosis
years (Min–Max)
46.9 (25–75) 57.4 (31–85) 50.7 (25–85) **†< 0.0001
Median age at BM diagnosis
years (Min–Max)
53.9 (30-79) 58.1 (31-85) 55.1 (30-85) **†† 0.008
Median time from initial cancer diagnosis 
to BM diagnosis
months (Min–Max)
33.5 (0-354) 1 (0-100) 13 (0-354) **†††< 0.0001
p-value was calculated with the following statistical tests: *c2; **T test; ***Log-rank; skewness: † 0.2, †† 0.1, †††2.4; cI — confidence interval
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this study confers some limitations to the collected 
data. In order to address this limitation, every elec-
tronic medical chart and imaging studies were re-
evaluated by an experienced neuro-radiologist and 
a neuro-oncologist, and variable definitions were 
stablished a priori. Beside this caveat, the study 
was performed by collecting data from a single 
center; therefore, a selection bias should also be 
considered. 
The historic affirmation that infratentorial BM 
have a worse prognosis than supratentorial ones 
[5] could be reconsidered in the palliative setting 
in the modern era, probably due to advances in 
systemic treatments including WBRT. Our results 
suggest that WBRT continues to be a useful tool in 
the management of patients with brain metastasis, 
and that its effectiveness in the palliative setting is 
similar for patients with infratentorial BM; also, 
chemotherapy administered after WBRT appears 
to provide a longer overall survival; however we 
consider that these results should be corroborated 
by future prospective studies.
table 2. subgroup analysis and survival outcomes according to brain metastases localization
Subgroup
Supratentorial 
n = 105 (40%)
Infratentorial 
n = 25 (10%)
Both 
n = 133 
(51%)
Total 













Breast 51 (48.6) 20 (80) 81 (60.9) 152 (57.8) 13 (9.9–16.1)
Number of 
BM
1 55 (52.4) 16 (64) 2 (1.5) 73 (27.8)
*< 0.0001
14 (10.7–17.3)
0.152–3 33 (31.4) 7 (28) 27 (20.3) 67 (25.5) 11 (6.9–15)
> 3 17 (16.2) 2 (8) 104 (78.2) 123 (46.8) 13 (10.3–15.7)
Location by 
side




right 37 (35.2) 11 (44) 3 (2.3) 51 (19.4) 12 (8.1–15.8)
Both 35 (33.3) 5 (20) 119 (89.5) 159 (60.5) 13 (10.6–15.3)
Middle line 1 (1) 4 (16) – 5 (1.9) 13 (10.8–15.1)
systemic 
metastasis




Inactive 9 (8.6) 1 (4) 14 (10.5) 24 (9.1) 15 (8.9–21)
Kps at BM 
diagnosis




50 – 2 (8) 8 (6) 10 (3.8) 19 (0–38)
60 2 (1.9) 1 (4) 6 (4.5) 9 (3.4) 6 (3–8.9)
70 15 (70) 3 (12) 30 (22.6) 48 (18.3) 12 (9.4–14.5)
80 44 (41.9) 11 (44) 37 827.8) 92 (35) 12 (9.3–14.6)
90 44 (41.9) 8 (32) 50 837.6) 105 (38.8) 15 (10.7–19.2)










33 (31.4) 5 (20) 34 (25.6) 72 (27.4) 11 (7.9–14)
> 12–24 
months
16 (15.2) 2 (8) 20 (15) 38 (14.4) 13 (9.2–16.7)
> 24–36 
months
9 (8.6) 7 (28) 7 (5.3) 23 (8.7) 15 (10.5–19.4)
> 36–48 
months
2 (1.9) 1 (4) 7 85.3) 10 83.8) 3 (1.9–4)
> 48–60 
moths
3 (2.9) 2 (8) 5 83.8) 10 (3.8) 8 (2.8–13.1)
> 60 
months
19 (18.1) 5 (20) 30 (22.6) 54 (20.5) 17 (12–21.9)






p-value was calculated with the following statistical tests: *c2, **T test, ***Log-rank; MOs — median overall survival after BM diagnosis; BM — brain metastasis; 
Kps — Karnofsky performance status; WBrT — whole brain radiotherapy; cTX — chemotheraphy
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conclusion
In patients with LC or BC that develop BM and 
are not candidates for surgical resection, WBRT 
appears to be effective for the palliation of BM, ir-
respective of their supra- or infratentorial location. 
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table 3. survival outcomes for brain metastases according to modality of treatment and localization
Localization /Treatment
WBRT 
n = 208 (79%)
WBRT/CTX 
(n = 55) (20.9)
Log-rank
n (%)
MOS in months 
(95% CI)
n (%)
MOS in months 
(95% CI)
supratentorial
n = 105 (40%)
89 (84.8) 12 (9.8–14.1) 16 (15.2) 26 (14.2–37.6) 0.253
Infratentorial

















MOs — median overall survival after BM diagnosis; WBrT — whole brain radiotherapy; cTX — chemotherapy
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